StreetInsider.com News Articles

Harrow re-launches VERKAZIA eye drops for pediatric eye condition

Wed, 10 Jun 2026 07:01:22 -0400

Harrow Inc. (NASDAQ: HROW) announced the re-launch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for treating vernal keratoconjunctivitis, a chronic allergic eye disease that primarily affects children.

The prescription therapy targets VKC, a condition that can cause severe itching, pain, light sensitivity, and potential corneal damage in pediatric patients. The disease typically begins in early childhood and may persist through adolescence, with seasonal flare-ups that can impact school performance and daily activities.

VERKAZIA is a calcineurin inhibitor immunomodulator designed to address the underlying inflammatory mechanisms of VKC. The drug provides an alternative to corticosteroids, which carry risks of glaucoma and cataract formation when

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Wed, 10 Jun 2026 07:00:00 -0400

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriers
VERKAZIA is indicated for the treatment of all forms of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children and may lead to sight-threatening conditions if left untreated or undertreated
VERKAZIA is a calcineurin inhibitor immunomodulator that targets the underlying inflammatory mechanisms of VKC and may reduce the need for steroid rescue, all of which are associated with risks such as glaucoma or cataract formation

NASHVILLE, Tenn., June

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Wed, 10 Jun 2026 07:00:00 -0400

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriers
VERKAZIA is indicated for the treatment of all forms of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children and may lead to sight-threatening conditions if left untreated or undertreated
VERKAZIA is a calcineurin inhibitor immunomodulator that targets the underlying inflammatory mechanisms of VKC and may reduce the need for steroid rescue, all of which are associated with risks such as glaucoma or cataract formation

NASHVILLE, Tenn., June

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Wed, 10 Jun 2026 07:00:00 -0400

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriers
VERKAZIA is indicated for the treatment of all forms of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children and may lead to sight-threatening conditions if left untreated or undertreated
VERKAZIA is a calcineurin inhibitor immunomodulator that targets the underlying inflammatory mechanisms of VKC and may reduce the need for steroid rescue, all of which are associated with risks such as glaucoma or cataract formation

NASHVILLE, Tenn., June

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Wed, 10 Jun 2026 07:00:00 -0400

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriers
VERKAZIA is indicated for the treatment of all forms of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children and may lead to sight-threatening conditions if left untreated or undertreated
VERKAZIA is a calcineurin inhibitor immunomodulator that targets the underlying inflammatory mechanisms of VKC and may reduce the need for steroid rescue, all of which are associated with risks such as glaucoma or cataract formation

NASHVILLE, Tenn., June

Form 8-K HARROW, INC. For: Jun 03

Wed, 03 Jun 2026 09:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26596609.html

Form 8-K HARROW, INC. For: Jun 03

Wed, 03 Jun 2026 09:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26596609.html

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

Wed, 27 May 2026 07:00:00 -0400

NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair’s 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.

The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

Wed, 27 May 2026 07:00:00 -0400

The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

Wed, 27 May 2026 07:00:00 -0400

The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

Wed, 27 May 2026 07:00:00 -0400

The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management

Form 4 HARROW, INC. For: May 18 Filed by: Graves Adrienne L

Tue, 19 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260519/26517091.html

Form 4 HARROW, INC. For: May 18 Filed by: Graves Adrienne L

Tue, 19 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260519/26517091.html

Form 4 HARROW, INC. For: May 18 Filed by: SILVERNAIL LAUREN P

Tue, 19 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260519/26517094.html

Form 4 HARROW, INC. For: May 18 Filed by: SILVERNAIL LAUREN P

Tue, 19 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260519/26517094.html

Form 4 HARROW, INC. For: May 15 Filed by: Shojaei Amir

Mon, 18 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260518/26514867.html

Form 4 HARROW, INC. For: May 15 Filed by: Shojaei Amir

Mon, 18 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260518/26514867.html

Form 4 HARROW, INC. For: May 14 Filed by: BOLL ANDREW R.

Fri, 15 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26499196.html

Form 4 HARROW, INC. For: May 14 Filed by: BOLL ANDREW R.

Fri, 15 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26499196.html

Form 4 HARROW, INC. For: May 14 Filed by: BAUM MARK L

Fri, 15 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26499213.html

Form 4 HARROW, INC. For: May 14 Filed by: BAUM MARK L

Fri, 15 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26499213.html

Harrow Health (HROW) PT Lowered to $60 at B.Riley

Thu, 14 May 2026 08:55:10 -0400

B.Riley analyst Mayank Mamtani lowered the price target on Harrow Health (NASDAQ: HROW) to $60.00 (from $65.00) while maintaining a Buy rating.

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Wed, 13 May 2026 10:13:46 -0400

MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Harrow, Inc. (Nasdaq: HROW) (“HROW”) has violated the federal securities laws after the company advised that VEVYE revenue of $20.9 million during the first quarter of 2026 was below expectations due to an estimated $8 million gross-to-net reduction associated with new commercial coverage for VEVYE.

Upon this news, HROW’s stock price fell 23.69% in trading on May 12, 2026. In particular, on HROW’s quarterly earnings call on May 12, 2026, several analysts inquired into the gross-to-net

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Wed, 13 May 2026 10:13:46 -0400

Upon this news, HROW’s stock price fell 23.69% in trading on May 12, 2026. In particular, on HROW’s quarterly earnings call on May 12, 2026, several analysts inquired into the gross-to-net

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Wed, 13 May 2026 10:13:00 -0400

Upon this news, HROW’s stock price fell 23.69% in trading on May 12, 2026. In particular, on HROW’s quarterly earnings call on May 12, 2026, several analysts inquired into the gross-to-net